miR-762/ BCL2L13分子轴在乳头状甲状腺癌组织中的表达及其对TPC-1细胞恶性生物学行为的影响
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:

内蒙古自治区卫健委卫生健康科技计划项目(202201275)


Expression of the miR-762/BCL2L13 axis in papillary thyroid carcinoma and its influence on the malignant biological behavior of TPC-1 cells
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    目的 探讨抑制miR-762表达对乳头状甲状腺癌(PTC)细胞TPC-1增殖和凋亡的影响及其机制。方法 采用qRT-PCR法检测83例PTC癌组织及癌旁组织中miR-762和Bcl-2样蛋白13(BCL2L13)mRNA的表达,并对两者表达水平进行相关性分析。采用生物信息学软件和双荧光素酶报告基因实验分析miR-762与BCL2L13的靶向关系。采用脂质体法将miR-762 inhibitor和BCL2L13 siRNA干扰质粒(si-BCL2L13)转染至TPC-1细胞中,qRT-PCR检测细胞中miR-762和BCL2L13 mRNA表达水平;MTT法和BrdU染色检测细胞增殖水平;流式细胞仪检测细胞凋亡水平;Western blot检测细胞中BCL2L13、Cleaved- caspase-3以及线粒体和胞浆中细胞色素C(Cyt C)等蛋白表达水平。结果 与癌旁组织比较,在PTC癌组织中miR-762表达水平升高,而BCL2L13 mRNA表达水平降低,且两者呈负相关性(r=-0.70,P<0.01)。双荧光素酶报告基因实验证实,BCL2L13是miR-762靶基因。抑制miR-762表达可明显下调TPC-1细胞中miR-762表达水平,上调BCL2L13 mRNA和蛋白表达,抑制细胞增殖,提高细胞凋亡水平,并上调Cleaved-caspase-3蛋白和胞浆中Cyt C蛋白表达水平,下调线粒体Cyt C蛋白表达。而干扰BCL2L13基因表达可显著下调TPC-1细胞中BCL2L13 mRNA和蛋白表达,促进细胞增殖,抑制细胞凋亡,上调线粒体Cyt C蛋白表达,下调Cleaved-caspase-3蛋白和胞浆中Cyt C蛋白表达。此外,干扰BCL2L13基因表达可显著逆转miR-762 inhibitor对TPC-1细胞增殖的抑制作用以及凋亡的促进作用。结论 miR-762在人PTC组织中高表达,抑制miR-762表达可诱导TPC-1细胞凋亡和抑制细胞增殖,其机制可能与靶向上调BCL2L13基因表达有关

    Abstract:

    Objective To explore the effect of inhibiting the expression of miR-762 on the proliferation and apoptosis of papillary thyroid cancer (PTC) cells TPC-1 and its mechanism. Methods, The qRT-PCR method was used to detect the expression of miR-762 and Bcl-2-like protein 13 (BCL2L13) mRNA in 83 cases of PTC cancer tissues and adjacent tissues, and the correlation between the expression levels of them was analyzed. Bioinformatics prediction software and dual luciferase reporter gene experiment were used to analyze the targeting relationship between miR-762 and BCL2L13. The liposome method was used to transfect miR-762 inhibitor and BCL2L13 siRNA interference plasmid (si-BCL2L13) into TPC-1 cells. qRT-PCR was used to measure the relative transcript levels of miR-762 and BCL2L13, cell proliferation level was detected by MTT and BrdU staining, apoptosis level was detected by flow cytometry, the expression levels of BCL2L13, Cleaved-caspase-3 and cytochrome C (Cyt C) in mitochondria and cytoplasm were detected by Western blot. Results Compared with the adjacent tissues, the expression level of miR-762 increased in PTC cancer tissues, while the expression level of BCL2L13 mRNA decreased, and there was a negative correlation between the two (r=-0.70, P<0.01). The double luciferase reporter gene experiment confirmed that BCL2L13 was the target gene of miR-762. Inhibition of miR-762 expression could significantly down-regulate the expression level of miR-762 in TPC-1 cells, up-regulate the expression of BCL2L13 mRNA and protein, inhibit cell proliferation, increase the level of apoptosis, and up-regulate the expression level of Cleaved-caspase-3 protein and cytoplasmic Cyt C protein, decrease the expression level of mitochondrial Cyt C protein. Interference with BCL2L13 gene expression could notably down-regulate BCL2L13 mRNA and protein expression in TPC-1 cells, promote cell proliferation, inhibit cell apoptosis, up-regulate mitochondrial Cyt C protein expression, and decrease Cleaved-caspase-3 protein and Cyt C protein expression in cytoplasm. In addition, interference with BCL2L13 gene expression could significantly reverse the inhibitory effect of miR-762 inhibitor on TPC-1 cell proliferation and the promotion of miR-762 inhibitor on apoptosis. Conclusion miR-762 is highly expressed in human PTC tissues, and inhibition of miR-762 expression can induce TPC-1 cell apoptosis and inhibit cell proliferation. The mechanism may be related to the targeted up-regulation of BCL2L13 gene expression

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2026-01-19
您是第位访问者
版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403 本网站支持 IPv6    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司